Loading... Please wait...


Our Newsletter

TMC207 (Bedaquiline) | ATP synthase inhibitor

  • TMC207 (Bedaquiline).jpg
  • TMC207 (Bedaquiline), 400x400px, png
Catalog #:

Product Description

TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1)

Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2)

Technical information:

Chemical Formula:   C32H31BrN2O2
CAS #:   843663-66-1
Molecular Weight:   555.5
Purity:   > 98%
Appearance:   white
Chemical Name:   (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol
Solubility:   Up to 2 mM in DMSO
Synonyms:   TMC207, TMC-207, Bedaquiline

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Matteelli et al., TMC207: the first compoudn of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931
2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the TMC207 (Bedaquiline) | ATP synthase inhibitor to your wish list.

You Recently Viewed...